Reckitt is sharpening its focus on consumer health and hygiene by putting its home care business up for sale and launching a strategic review of infant nutrition operation Mead Johnson.
Mead Johnson and home care are now considered non-core operations after management concluded both businesses no longer satisfied the company’s “three principles” relating to long-term growth prospects, gross margin strength
Mead Johnson
The Mead Johnson Nutrition business – which markets infant nutrition brands such as Enfamil and Nutramigen – generated 2023 sales of £2.4bn, down 4.0% like-for-like on the prior-year. Reckitt said it will consider “all strategic options to maximize shareholder value” for a business it acquired in 2017 for $16.6bn.
Mead Johnson is in the midst of complex litigation with plaintiffs’ alleging the firm failed to warn its Enfamil products increased the risk of necrotizing enterocolitis in babies
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?